STOCK TITAN

Evolus, Inc. - EOLS STOCK NEWS

Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.

Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company headquartered in Newport Beach, California. Established in 2012, Evolus is dedicated to providing innovative medical aesthetic products to physicians and their patients in the United States and Europe. The company's flagship product, Jeuveau, is a proprietary 900 kilodalton purified botulinum toxin type A formulation. It is specifically designed for the temporary improvement in the appearance of moderate to severe glabellar lines, commonly known as frown lines, in adults.

Evolus operates primarily in the self-pay aesthetic market, a unique segment where medical products are purchased by physicians and other customers and then sold to consumers or used in aesthetic procedures. This customer-centric approach positions Evolus to meet the growing demand for non-surgical cosmetic enhancements.

Recent Achievements:

  • Successful expansion of Jeuveau sales across the United States and Europe.
  • Strong partnerships with distribution partners in Canada, generating significant service revenue.
  • Continued investment in research and development to enhance and expand their product offerings.

Current Projects:

  • Exploring new formulations and applications for botulinum toxin type A to address other aesthetic and medical needs.
  • Enhancing digital platforms to improve customer engagement and support for medical professionals.

With a firm commitment to providing high-quality aesthetic solutions, Evolus, Inc. is poised for future growth and innovation in the beauty industry.

Rhea-AI Summary

Evolus reported a remarkable 235% year-over-year increase in net revenue, reaching $26.1 million for Q2 2021, significantly exceeding its annualized revenue run rate goal of $100 million.

The company ended the quarter with a strong cash position of $131.7 million and is on track for a European launch in early 2022, targeting a potential $470 million market. Key drivers included increased Jeuveau® sales and a growing customer base, with over 6,000 purchasing accounts and 200,000 registered in its loyalty program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
none
-
Rhea-AI Summary

Evolus, a performance beauty company, will announce its second quarter 2021 financial results on August 4, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, including a Q&A session. Interested participants can join the call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international) and via their Investor Relations webpage. Evolus is known for its FDA-approved aesthetic neurotoxin, Jeuveau®, which aims to transform the beauty market. For more information, visit www.evolus.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
conferences
-
Rhea-AI Summary

Evolus, Inc. (Nasdaq: EOLS) has appointed David K. Erickson as Vice President of Investor Relations, effective immediately. With over 25 years of experience in investor relations and the healthcare sector, Erickson is expected to enhance the company's strategic investor communications. His prior roles include positions at Establishment Labs Holdings and Edwards Lifesciences. Evolus aims to expand its global presence, including a European launch anticipated in early 2022, which will further benefit from Erickson's industry connections and expertise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
management
Rhea-AI Summary

Evolus, Inc. (Nasdaq: EOLS) announced a peer-reviewed article in Dermatologic Surgery highlighting prabotulinumtoxinA (Jeuveau®)'s efficacy for treating glabellar lines in patients with Skin of Color (SOC). The study compared outcomes in 492 patients and found responder rates were slightly lower for SOC patients. Notably, the headache was the most common adverse event, affecting 12.1% of SOC patients. With growing demand from SOC patients, understanding the effectiveness and safety differences between SOC and non-SOC populations becomes crucial for dermatologists.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary

Evolus, Inc. (Nasdaq: EOLS) has appointed Dan Stewart as Vice President and General Manager of its International business. With over 20 years of experience in medical aesthetics, Stewart is expected to lead Evolus' global expansion, beginning with the European launch of Nuceiva™ in early 2022. The Chief Marketing Officer praised Stewart's successful track record. Evolus is known for its customer-centric approach and innovative products, including Jeuveau®, a unique neurotoxin approved for aesthetics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
management
-
Rhea-AI Summary

Evolus, Inc. (Nasdaq: EOLS) reported Q1 2021 net revenues of $12.2 million, a 16% increase from the previous year, aided by the resolution of an International Trade Commission (ITC) case. The company's pro forma cash position stood at $140 million as of March 31, 2021. The U.S. Jeuveau® business is on track for a $100 million annual revenue run rate in Q2 2021. Moreover, operating expenses decreased by 25.7% year-over-year, while gross margins are expected to stabilize post-September 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
none
Rhea-AI Summary

Evolus, a performance beauty company, announced two Phase II peer-reviewed studies published in Aesthetic Surgery Journal showcasing the safety and efficacy of repeat doses of Jeuveau® for treating glabellar lines. Conducted to support regulatory approval in North America and Europe, the studies indicate prolonged use is safe, with decreasing adverse events noted over time. Jeuveau® employs patented Hi-Pure™ technology that minimizes antibody formation. The studies confirm the effectiveness of Jeuveau® as a viable neurotoxin alternative for consumers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
Rhea-AI Summary

Evolus, a performance beauty company, will report its first quarter 2021 financial results on May 12, 2021, after U.S. market close. A conference call will follow at 4:30 p.m. ET, providing a business update and a Q&A session. Domestic callers can access the call at (866) 916-2317, while international callers should use (703) 925-2662, with conference ID 7749489. A replay will be available until May 19, 2021. The event can also be streamed live via the Evolus Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences
-
Rhea-AI Summary

Evolus, a performance beauty company, will participate in the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, from 3:30 PM to 4:10 PM ET. The event will feature a fireside chat and 1x1 meetings, allowing investors to engage with management. An audio webcast of the discussion will be accessible on the company's investor relations page and available for replay for 90 days post-event. Evolus is known for its aesthetic neurotoxin, Jeuveau®, approved by the FDA in 2019, and aims to transform the aesthetic market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
Rhea-AI Summary

Evolus announced the pricing of a public offering of 9,000,000 shares of common stock at $9.50 each, aiming for gross proceeds of $85.5 million. The offering, expected to close around April 26, 2021, includes an option for underwriters to purchase an additional 1,350,000 shares. Proceeds will fund Jeuveau® growth in the U.S., European pre-launch activities, and general corporate purposes. The offering is managed by SVB Leerink, Stifel, and Cantor, with details available in the prospectus filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.86%
Tags

FAQ

What is the current stock price of Evolus (EOLS)?

The current stock price of Evolus (EOLS) is $10.84 as of December 23, 2024.

What is the market cap of Evolus (EOLS)?

The market cap of Evolus (EOLS) is approximately 689.6M.

What is Evolus, Inc.?

Evolus, Inc. is a performance beauty company that provides medical aesthetic products to physicians and patients in the U.S. and Europe.

What is Jeuveau?

Jeuveau is a proprietary 900 kilodalton purified botulinum toxin type A formulation used to temporarily improve the appearance of moderate to severe frown lines in adults.

Where is Evolus headquartered?

Evolus is headquartered in Newport Beach, California.

When was Evolus founded?

Evolus was founded in 2012.

What market does Evolus primarily serve?

Evolus primarily serves the self-pay aesthetic market.

How does Evolus generate revenue?

Evolus generates product revenue from sales of Jeuveau in the U.S. and Europe, and service revenue from distribution partners in Canada.

What recent achievements has Evolus made?

Evolus has expanded Jeuveau sales in the U.S. and Europe and strengthened partnerships with Canadian distribution partners.

What are Evolus's current projects?

Evolus is working on new formulations and applications for botulinum toxin type A and enhancing digital platforms for better customer engagement.

Who are Evolus's primary customers?

Evolus's primary customers are physicians and other medical professionals who purchase their products for aesthetic procedures.

What is the significance of Jeuveau's formulation?

Jeuveau's formulation is significant because it offers a high-quality, non-surgical option for reducing frown lines, meeting the growing demand for aesthetic enhancements.

Evolus, Inc.

Nasdaq:EOLS

EOLS Rankings

EOLS Stock Data

689.57M
50.17M
12.31%
80.25%
8.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NEWPORT BEACH